Zydus Lifesciences, an innovation-led life-sciences company with an international presence, has signed an agreement with ...

Study at the University of Colorado Anschutz Cancer Center builds on preclinical data showing that cirtuvivint plus PARP inhibition overcame resistance in preclinical models of high‑grade serous ovari ...

Zydus partners with Myriad Genetics to introduce advanced cancer-risk assessment tests, enhancing precision diagnostics in India.

Zydus Lifesciences partners with Myriad Genetics to launch cancer-risk assessment diagnostic tests in India. Precision ...

Zydus Lifesciences has partnered with US-based Myriad Genetics to bring advanced cancer risk and prognostic tests to India, aiming to boost personalized oncology care.

As part of this agreement, Zydus will exclusively market, create awareness, access and engage clinicians on three of Myriad Genetics' broadly validated diagnostic platforms, MyRisk Hereditary Cancer ...

Zydus Lifesciences Ltd on Friday said it has signed an exclusive agreement with Myriad Genetics of US to launch cancer-risk ...

Zydus Lifesciences Limited ( ($IN:ZYDUSLIFE) ) has issued an announcement. Zydus Lifesciences has signed an exclusive agreement with US-based ...

ICMR funds new clinical trial to test effective dosing strategy of high-cost cancer drug PARP inhibitor: Our Bureau, Mumbai Monday, December 15, 2025, 17:10 Hrs [IST] Funded by th ...

The Every Woman study- Low and low-middle-income country edition, published  in the prestigious journal The Lancet on 11th ...

A pair of well-known marijuana compounds work in tandem to target ovarian cancer cells In A Nutshell CBD and THC killed ...

Here are the top 5 ovarian cancer articles of 2025; stay up-to-date with all the ovarian cancer content from The American ...